Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
|Title:||Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?|
|Source:||Targeted oncology, 4 (2|
|Added Details:||Azambuja, Evandro
Bedard, Philippe L
|Document Type:||Electronic Resource|
|Abstract:||Trastuzumab, a monoclonal antibody that blocks HER-2 receptor, improves the survival of women with HER-2-positive early and advanced breast cancer when given with chemotherapy. Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2, is approved for the treatment of metastatic breast cancer patients after failure of prior anthracycline, taxanes and trastuzumab therapies in combination with capecitabine. Importantly, cardiac toxicity, manifested as symptomatic congestive heart failure or asymptomatic left ventricular ejection fraction decline, has been reported in some of the patients receiving these novel anti-HER-2 therapies, particularly when these drugs are used following anthracyclines, whose cardiotoxic potential has been recognized for decades. This review will focus on the incidence, natural history, underlying mechanisms, management, and areas of uncertainty regarding trastuzumab-and lapatinib-induced cardiotoxicity.
|Index Terms:||Sciences bio-médicales et agricoles, Adjuvants, Immunologic -- administration & dosage, Anthracyclines -- administration & dosage, Antibodies, Monoclonal -- administration & dosage, Antibodies, Monoclonal -- adverse effects, Breast Neoplasms -- immunology, Breast Neoplasms -- mortality, Breast Neoplasms -- pathology, Breast Neoplasms -- physiopathology, Breast Neoplasms -- therapy, Drug Resistance, Neoplasm, Female, Heart Failure -- chemically induced, Humans, Oxidative Stress, Protein Kinase Inhibitors -- administration & dosage, Protein Kinase Inhibitors -- adverse effects, Quinazolines -- administration & dosage, Quinazolines -- adverse effects, Receptor, Epidermal Growth Factor -- antagonists & inhibitors, Receptor, erbB-2 -- antagonists & inhibitors, Receptor, erbB-2 -- immunology, Survival Rate, Ventricular Outflow Obstruction -- chemically induced, Anti-HER-2 therapies, Breast cancer, Cardiotoxicity, Lapatinib, Trastuzumab, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article|
|Availability:||Open access content. Open access content|
|Note:||No full-text files
|Other Numbers:||EQY oai:dipot.ulb.ac.be:2013/52366
|Contributing Source:||UNIVERSITE LIBRE DE BRUXELLES
From OAIster®, provided by the OCLC Cooperative.
|Description not available.|